Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Performance analysis of distributed applications by suitability functions

A simple programming model of distributed-memory message-passing computer systems is first applied to describe the couple architecture/application by two sets of parameters. The node timing formula is then derived on the basis of scalar, vector and communication components. A set of suitability functions, extracted from the performance formulae, are defined. These functions are applied as an example to the performance analysis of the 1-dimensional FFT benchmark from the GENESIS benchmark suite. The suitability functions could also be useful for comparative performance analysis of both existing distributed-memory systems and new architectures under development

The GENESIS benchmark suite: current state and results

The motivation behind the development of the GENESIS benchmark suite has been to assemble benchmarks for a range of important scientific and engineering problems, which require high performance computing. The suite is being used to evaluate the relative strengths and weaknesses of current distributed-memory (DM) machines and to enable predictions of performance on future parallel computer architectures. In this paper the current release of the GENESIS benchmarks is first presented. Both message-passing and subset HPF versions exist for most of the codes in addition to the standard Fortran77 versions, with the PARMACS macros being used to express the necessary extensions to Fortran77 for task creation and message passing in the distributed versions, and for conferring portability across target systems. Some recent results from selected benchmarks running on the Intel iPSC/860 and the Meiko i860 Computing Surface are finally described and related to basic system parameters

The GENESIS Distributed-Memory Benchmarks

The genesis distributed-memory benchmarks represent a significant step forward in the evaluation of distributed-memory MIMD systems. The initial version of this benchmark suite was augmented and modified in order to evaluate the suprenum computer. This augmented suite has now been further modified to allow the benchmarks to be run on several important distributed systems without further code modification. This paper briefly describes the benchmark suite and outlines the methodology employed to run the benchmarks and interpret timing measurements. Some preliminary results from selected benchmarks running on the Intel ipsc/860 and the Meiko i860 Computing Surface are described and related to basic system parameters. The paper concludes with the possible future evolution of the suite